Panomifene Explained

Panomifene (INN; developmental codes GYKI 13504 and EGIS 5650) is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group related to tamoxifen that was under development as an antineoplastic agent by Egis Pharmaceuticals and IVAX Drug Research Institute in the 1990s for the treatment of breast cancer, but it was never marketed.^{[1] [2] [3] [4] [5] [6]} It reached phase II clinical trials before development was terminated. The drug was described in 1981.

Notes and References

1. Book: Elks J . The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 14 November 2014. Springer. 978-1-4757-2085-3. 930–.
2. Web site: Panomifene . AdisInsight . Springer Nature Switzerland AG .
3. Book: von Angerer E . Antiestrogens and Partial Agonists . Oettel M, Schillinger E . Estrogens and Antiestrogens I: Physiology and Mechanisms of Action of Estrogens and Antiestrogens. https://books.google.com/books?id=0BfrCAAAQBAJ&pg=PA60 . 6 December 2012. Springer Science & Business Media. 978-3-642-58616-3. 60–.
4. Book: Sitruk-Ware R . Pharmacological Different Administration Routes - Oral vs Transdermal. Oettel M, Schillinger E . Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. https://books.google.com/books?id=wBvyCAAAQBAJ&pg=PA292. 6 December 2012. Springer Science & Business Media. 978-3-642-60107-1. 292–.
5. Book: Koike T, Akita M . Visible-Light-Induced Redox Reactions by Ruthenium Photoredox Catalyst. Dixneuf PH, Bruneau C . Ruthenium in Catalysis. https://books.google.com/books?id=sjndBAAAQBAJ&pg=PA385. 18 October 2014. Springer. 978-3-319-08482-4. 385–.
6. Borvendég J, Hermann I, Csuka O . Antiestrogens, antiandrogens . Acta Physiologica Hungarica . 84 . 4 . 405–406 . 1996 . 9328614 .